NVision, founded in 2015 and based in Ulm, Germany, has developed a quantum technology that enhances medical imaging by leveraging new advances in quantum physics. Their hyperpolarization technology permits the assessment of human and animal metabolism by standard MRI, enabling advanced preclinical and clinical applications, including novel cancer diagnosis and monitoring of response to therapy. The company plans to deliver its first polarizers to users in 2023.